FORTE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.548 USD | +14.17% |
|
+9.60% | -33.31% |
| 05-30 | Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target | MT |
| 05-13 | Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 467.2 | 31.57 | 21 | 29.86 | 17.49 | - | - |
| Enterprise Value (EV) 1 | 408.4 | 31.57 | 21 | 29.86 | 17.49 | 17.49 | 17.49 |
| P/E ratio | -5.76 x | -1.38 x | -1.25 x | - | - | - | - |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 12,831 | 14,754 | 21,000 | 36,335 | 36,442 | - | - |
| Reference price 2 | 36.41 | 2.140 | 1.000 | 0.8217 | 0.5480 | 0.5480 | 0.5480 |
| Announcement Date | 16/03/21 | 31/03/22 | 31/03/23 | 18/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -46.28 | - | - | - | -33.85 | -40.72 | -55.37 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -46.49 | - | - | - | - | - | - |
| Net income | -4.069 | -46.49 | -21.71 | -13.88 | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS | -0.4100 | -6.320 | -1.550 | -0.8000 | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 25/03/20 | 16/03/21 | 31/03/22 | 31/03/23 | 18/03/24 | - | - | - |
1USD in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | - | - | -7.804 | -8.182 | -8.708 | -9.157 | -9.83 | -10.05 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
| Net income | -3.035 | - | -8.896 | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS | -0.2100 | - | -0.4200 | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/08/22 | 14/11/22 | 14/08/23 | 13/11/23 | 18/03/24 | 13/05/24 | - | - | - | - | - |
1USD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 58.8 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 25/03/20 | 16/03/21 | 31/03/22 | 31/03/23 | 18/03/24 | - | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.548
USD
Average target price
3.375
USD
Spread / Average Target
+515.88%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.31% | 17.49M | |
| +16.13% | 122B | |
| +19.65% | 115B | |
| +21.22% | 26.64B | |
| -23.84% | 19.91B | |
| -17.47% | 16.32B | |
| -45.95% | 15.52B | |
| -19.28% | 15.49B | |
| +63.81% | 14.83B | |
| +1.94% | 13.67B |
- Stock Market
- Equities
- FBRX Stock
- Financials Forte Biosciences, Inc.
